This article first appeared on GuruFocus.

LifeStance Health Group Inc (NASDAQ:LFST) is set to release its Q3 2025 earnings on Nov 6, 2025. The consensus estimate for Q3 2025 revenue is $355.60 million, and the earnings are expected to come in at -$0.01 per share. The full year 2025's revenue is expected to be $1.41 billion and the earnings are expected to be -$0.02 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 3 Warning Signs with LFST.

Is LFST fairly valued? Test your thesis with our free DCF calculator.

Over the past 90 days, revenue estimates for LifeStance Health Group Inc (NASDAQ:LFST) have increased from $1.41 billion to $1.41 billion for the full year 2025. For 2026, revenue estimates have increased from $1.61 billion to $1.61 billion. Earnings estimates for the full year 2025 have improved from -$0.06 per share to -$0.02 per share, while for 2026, they have remained steady at $0.02 per share.

In the previous quarter ending on 2025-06-30, LifeStance Health Group Inc's (NASDAQ:LFST) actual revenue was $345.31 million, which beat analysts' revenue expectations of $345.22 million by 0.03%. LifeStance Health Group Inc's (NASDAQ:LFST) actual earnings were -$0.01 per share, which exceeded analysts' earnings expectations of -$0.034 per share by 70.59%. Following the release of the results, LifeStance Health Group Inc (NASDAQ:LFST) saw an increase of 13.21% in one day.

Based on the one-year price targets offered by 6 analysts, the average target price for LifeStance Health Group Inc (NASDAQ:LFST) is $8.33, with a high estimate of $10.00 and a low estimate of $6.50. The average target implies an upside of 67.00% from the current price of $4.99.

According to GuruFocus estimates, the estimated GF Value for LifeStance Health Group Inc (NASDAQ:LFST) in one year is $9.51, suggesting an upside of 90.58% from the current price of $4.99.

Based on the consensus recommendation from 8 brokerage firms, LifeStance Health Group Inc's (NASDAQ:LFST) average brokerage recommendation is currently 1.8, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.